| Literature DB >> 35088520 |
Tomohiro Akutsu1, Takeo Fujita1, Daisuke Kajiyama1, Asako Ozaki1, Kazuma Sato1, Hisashi Fujiwara1, Takashi Kojima2, Hiroyuki Daiko3.
Abstract
BACKGROUND: The first choice of an esophageal substitute after esophagectomy for cancer is the stomach. However, the colon must be considered for reconstruction in specific situations. The purpose of this study was to clarify the frequency and clinical features of patients who underwent colon interposition in thoracic esophagectomy and to investigate the postoperative complications and survival.Entities:
Keywords: anastomotic leak; cancer; colon; esophagectomy; surgical anastomosis
Mesh:
Year: 2022 PMID: 35088520 PMCID: PMC8930463 DOI: 10.1111/1759-7714.14332
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.500
FIGURE 1Patient selection diagram between January 2010 and March 2020, 1561 patients underwent surgery at the Department of Esophageal Surgery, National Cancer Center Hospital East, Japan; 88 (5.6%) patients underwent esophageal reconstruction with colon interposition. The excluded cases are shown on the right
Patients' characteristics
| Variable | Value ( |
|---|---|
| Age, y (SD) | 70.7 (7.91) |
| Male/female | 82/6 (93.2/6.8%) |
| Performance status (0/1/2) | 62/25/1 (70.5/28.4/1.1%) |
| Body mass index mean (SD) (kg/m2) | 19.33 (2.84) |
| Medical history | |
| Diabetes mellitus | 14 (15.9%) |
| Hypertension | 38 (43.2%) |
| Heart disease | 12 (13.6%) |
| Other cancer | 30 (34.1%) |
| Respiratory disease | 10 (11.4%) |
| Gastric/duodenal ulcer | 30 (34.1%) |
| Alcohol | 74 (75%) |
| Tobacco | 74 (77.5%) |
| Brinkman index (SD) | 733.4 (510) |
| Reason for colon reconstruction | |
| Post‐gastrectomy | 65 (72.7%) |
| Complication of gastric cancer | 21 (25.1%) |
| Gastric invasion | 1 (1.1%) |
| Gastric conduit cancer | 1 (1.1%) |
| Laboratory data | |
| Hb (SD) (g/L) | 118 (17.0) |
| Alb (SD) (g/L) | 39.1 (4.5) |
| Histological type (SCC /adenocarcinoma) | 84/4 (95.5/4.6%) |
| Study period 2010–2014/2015–2020 | 40/48 (45.5%/54.5%) |
| Location (Ce/Ut/Mt/Lt) | 1/7/39/39 (1.1/8.0/44.3/44.3%) |
| cT (1a/1b/2/3/4a/4b) | 35/10/38/3/1 (39.7/11.4/43.2/3.3/1.1%) |
| cN (0/1/2/4) | 38/24/21/5 (43.2/27.3/23.9/5.7%) |
| cM (0/1/1[104]) | 78/8/2 (88.6/9.3/2.2%) |
| cStage (I/II/III/IVA/IVB) | 31/17/28/3/9 (35.2/19.3/31.8/3.4/10.2%) |
| cStage III/IV | 40 (45.5%) |
Note: Values are N (%) unless otherwise indicated.
Abbreviations: Alb, albumin; Ce, cervical; cM, clinical metastasis stage; cN, clinical node stage; cStage, cancer stage; cT, clinical tumor stage; Hb, hemoglobin; Lt, lower thoracic; Mt, mid‐thoracic; SCC, squamous cell carcinoma; SD, standard deviation; Ut, upper thoracic.
Details of the preoperative treatments and operations
| Variable | Value ( |
|---|---|
| Preoperative treatment | 47 (53.4) |
| None | 41 (46.6) |
| DCF 1/2/3 cycles | 3/2/14 (3.4/2.3/15.9) |
| FP 1/2 cycles | 3/12 (3.4/13.6) |
| FOLFOX | 1 (1.1) |
| TS‐1 | 2 (2.3) |
| CRT | 6 (6.8) |
| ESD | 3 (3.4) |
| RT | 1 (1.1) |
| Operation approach | |
| Thoracotomy | 33 (37.5) |
| Thoracoscopic | 46 (52.3) |
| Mediastinoscopic | 9 (10.2) |
| Operation time, min | 413.0 (270.2–476.0) |
| Total blood loss, g | 268.5 (124.7–521.0) |
| Reconstruction route | |
| Retrosternal | 76 (86) |
| Posterior mediastinal | 9 (10) |
| Subcutaneous | 3 (3.4) |
| Two‐phase operation | 23 (26.1) |
| Preserved ileocolic artery | 34 (38.6) |
| Cervical anastomosis | |
| Totally mechanical collard | 42 (47.7) |
| Hand‐sewn | 43 (48.9) |
| Circular stapler | 3 (3.4) |
Note: Values are N (%) or median (interquartile range).
Abbreviations: CRT, chemoradiotherapy regimen consisting of 41.4 Gy radiotherapy plus 2 cycles of 5‐fluorouracil/cisplatin; DCF, docetaxel 70 mg/m2 and cisplatin 70 mg/m2 on day 1 and a continuous infusion of 5‐fluorouracil 750 mg/m2/day for 5 days; ESD, endoscopic submucosal dissection; FOLFOX, oxaliplatin 85 mg/m2, levofolinate calcium 200 mg/m2, and 5‐fluorouracil 400 mg/m2 on day 1 and a continuous infusion of 5‐fluorouracil 2400 mg/m2/day for 2 days; FP, cisplatin 80 mg/m2 on day 1 and a continuous infusion of 5‐fluorouracil 1150 mg/m2/day for 5 days; RT, radiotherapy.
Complications and postoperative hospital stay
| Variable | Value ( |
|---|---|
| Clavien–Dindo grade ≤III | 37 (42) |
| Anastomotic leakage | 23 (26.1) |
| Anastomotic stenosis | 10 (11.3) |
| Respiratory complication | 14 (15.9) |
| Chylothorax | 1 (1.1) |
| Ileus | 6 (6.8) |
| Necrosis of the elevated intestine | 1 (1.1) |
| Clavien–Dindo grade ≥II | 7 1 (80.7) |
| Postoperative hospital stay | 22.0 0 (16–31) |
| In‐hospital death | 4 (4.5) |
Note: Values are N (%) or median (interquartile range).
Univariate and multivariate analysis of Clavien–Dindo grade ≤ III complications
| OR | Univariate analysis 95% CI |
| OR | Multivariate analysis 95% CI |
| |
|---|---|---|---|---|---|---|
| Patient background factors | ||||||
| Age, y | 1.030 | 0.972–1.08 | 0.353 | |||
| Body mass index | 0.925 | 0.796–1.07 | 0.308 | |||
| Performance status | 1.63 | 0.677–3.93 | 0.275 | |||
| Study period: 2015–2020 | 0.264 | 0.109–0.641 | 0.00327 | 0.604 | 0.100–3.65 | 0.583 |
| Hb | 1.030 | 0.803–1.32 | 0.825 | |||
| Alb | 0.782 | 0.309–1.98 | 0.604 | |||
| Stage III/IV cancer | 0.692 | 0.298–1.61 | 0.392 | |||
| Surgical factors | ||||||
| Preoperative treatment | 0.434 | 0.184–1.02 | 0.0562 | 0.631 | 0.244–1.63 | 0.3410 |
| Thoracotomy | 1.63 | 0.682–3.89 | 0.272 | |||
| Thoracoscopy | 0.577 | 0.248–1.34 | 0.202 | |||
| Two‐phase operation | 1.810 | 0.689–4.78 | 0.228 | |||
| Preserved ileocolic artery | 1.21 | 0.513–2.86 | 0.662 | |||
| Totally mechanical collard anastomosis | 0.267 | 0.11–0.645 | 0.00335 | 0.464 | 0.0816–2.64 | 0.387 |
| Hand sewn anastomosis | 2.78 | 1.17–6.59 | 0.0203 | |||
Abbreviations: Alb, albumin; CI, confidence interval; Hb, hemoglobin; OR, odds ratio.
FIGURE 2Overall survival of all patients who underwent colon interposition. The 3‐year survival rate was 54.2%, and the 5‐year survival rate was 42.2%. The median overall survival was 1239 days. CI, confidence interval
Univariate and multivariate analysis of overall survival
| HR | Univariate analysis 95% CI |
| HR | Multivariate analysis 95% CI |
| |
|---|---|---|---|---|---|---|
| Patient background factors | ||||||
| Age, y | 1.077 | 1.029–1.127 | 0.0014 | 1.08 | 1.039–1.14 | 0.00035 |
| Body mass index | 0.904 | 0.777–1.05 | 0.192 | |||
| Performance status | 2.260 | 0.920–5.57 | 0.075 | |||
| Hb | 0.846 | 0.655–1.09 | 0.200 | 0.80 | 0.671–1.154 | 0.13 |
| Alb | 0.387 | 0.145–1.04 | 0.0586 | |||
| Stage III /IV | 1.736 | 0.939–3.207 | 0.0781 | 1.704 | 0.914–3.176 | 0.093 |
| Study period: 2015–2020 | 0.7576 | 0.401–1.432 | 0.3926 | |||
| Surgical factors | ||||||
| Preoperative treatment | 0.749 | 0.406–1.383 | 0.356 | |||
| Thoracotomy | 1.65 | 0.8994–3.051 | 0.1053 | |||
| Thoracoscopy | 0.478 | 0.2565–0.8925 | 0.0205 | |||
| Two‐phase operation | 1.428 | 0.7418–2.748 | 0.2864 | |||
| Clavien–Dindo grade ≥III | 1.836 | 0.9744–3.459 | 0.0601 | 1.739 | 0.913–3.31 | 0.0918 |
| Clavien–Dindo grade ≤II | 1.715 | 0.7205–4.082 | 0.2228 |
Abbreviations: Alb, albumin; CI, confidence interval; Hb, hemoglobin; HR, hazard ratio.
FIGURE 3ROC curve of age for overall survival. We evaluated survival time at 1239 days (median overall survival); the AUC was 0.68. The ROC cut‐off value was 71 years, for overall survival, with a sensitivity and specificity of 0.639 and 0.641, respectively. AUC, area under the curve; ROC, receiver operating characteristic